Bid to restrict industry-backed CME rebuffed, again

Share this article:
A third attempt by an AMA ethics council asking physicians and medical institutions to curb industry funding for professional educational activities was rebuffed yesterday.

The proposals, contained in a report from AMA's Council on Ethical and Judicial Affairs (CEJA), would have required CME providers to only accept funds from “sources that have no direct financial interest in a physician's clinical recommendations,” except in certain cases. At the AMA's semi-annual policymaking meeting, its House of Delegates voted to send the entire report back to CEJA for further study.

“The rejection by the House of Delegates shows a commitment to CME funding and academic freedom,” wrote Rockpointe Medical Education president Thomas Sullivan in the blog Policy and Medicine. “The AMA members are not willing to give up their rights to collaborate with industry and give up commercial support of CME especially in these tough economic times.”

At a committee meeting prior to the vote, 25 speakers representing 24 organizations spoke against adoption of the CEJA recommendations, according to Sullivan, while in favor were 10 speakers representing CEJA, the AMA's Council on Medical Education and other organizations.

The last time delegates sent a CEJA proposal back to committee was in June. That proposal sought to delineate “ethically preferable” or “ethically permissible” CME funding practices. A 2008 proposal—also shelved—had called for an all-out ban on commercial support.

In a statement, AMA board chair Dr. Rebecca Patchin said CEJA “will re-examine the issue and present a revised report at a later meeting,” adding that AMA “already has existing ethical policy to govern physician relationships with the pharmaceutical, biotechnology and medical device industry.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...